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between days 45 and 100. Median age was 34 years (range 10-56);
78 had standard risk (SR) disease in ﬁrst remission or ﬁrst chronic
phase of CML, the remaining 79 had high risk (HR) disease. The
day 30 post-transplant lymphocyte count (LC30) was available in
154 patients and day 30 lymphocyte subset analysis was performed
in 54. Median LC30 was 400/	l, (range 10-3295) and 150/	l,
(range 6-1005) for CD56, CD16 CD3- NK cells (NK30).
Eighty-ﬁve patients (514%) survive (median 1392 days). Patients
with LC30 above median had signiﬁcantly (p0.002) faster neu-
trophil engraftment (18 vs.13 days), platelet engraftment (22 vs.18
days) and signiﬁcantly fewer febrile days before day30 pos-trans-
plantation (8.6 vs. 5). Patients with  median LC30 had signiﬁ-
cantly better transplant outcome: survival 71 vs. 36 p0.0001; DFS
71 vs. 31 %, p0.001; NRM 10 vs. 38, p0.001; relapse 22 vs. 51
%, p0.004;  II aGVHD 34 vs. 51 p0.05. In multivariate
analysis only disease risk and LC30 emerged as independent prog-
nostic factors: LC30 above 400/	l was associated with improved
survival (RR 4.3), DFS (RR 4.5), less relapse (RR 10.3), NRM (RR
3.3) and aGVHD (RR 2.3). LC30 impacted outcome of both HR
and SR disease groups. In the subset of 54 patients where NK cells
were quantitated LC30 and NK30 were highly correlated
(p0.001) and NK30 above 150/	l was also associated with im-
proved transplant outcome: In multivariate analysis, SR disease and
NK30 150/	l were the only independent factors associated with
better survival (RR 3), DFS (RR 3), less relapse (RR 4.8), less NRM
(RR 3) and less aGVHD (RR 5.3). This study did not deﬁne
whether LC30 is a surrogate for NK cell count or whether both are
a surrogate for another undetected prognostic factor. However the
inverse relationship between NK count and aGVHD raise the
possibility of an NK-mediated effect occurring via elimination of
host antigen presenting cells as described by others.
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TREATMENT OF STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE
WITH MONOCLONAL ANTIBODIES IN CHILDREN
Schechter, T.1, Afzal, S.1, Finkelstein, Y.1, Koren, G.1, Doyle, J.1,
Dupuis, L.L.1 1The Hospital for Sick Children, Toronto, ON, Canada.
Introduction: Acute graft-versus-host disease (aGVHD) carries
a major risk of morbidity and mortality in patients undergoing
hematopoietic stem cell transplantation (HSCT). The prognosis is
poor if aGVHD does not respond to corticosteroid treatment.
Recently, monoclonal antibodies such as daclizumab, a humanized
monoclonal IgG1, and inﬂiximab, a chimeric monoclonal antibody
that binds the precursor of tumor-necrosis factor-alfa, have shown
promising results in the treatment of corticosteroid-resistant
aGVHD. The reported complete response rate to monoclonal
antibody therapy in adults with aGVHD reaches as high as 47%.
Data describing the efﬁcacy of monoclonal antibodies in children
with corticosteroid-resistant aGVHD are limited.
Methods: We conducted a retrospective analysis to evaluate the
efﬁcacy of daclizumab and/or inﬂiximab in children diagnosed with
steroid-resistant aGVHD in the Hospital for Sick Children, To-
ronto, from July 2002 to December 2005. Corticosteroid-resistant
aGVHD was deﬁned as aGVHD which did not response or wors-
ened after a minimum of 5 days of corticosteroid therapy. Com-
plete response (CR) was deﬁned as full recovery without any signs
of aGVHD; partial response (PR) was deﬁned as improvement of
aGVHD symptoms in at least one organ without worsening in
other organs.
Results: Sixteen children were treated for aGVHD, twelve of
them had aGVHD grade 3 or 4. The organs involved were gut
(n6), skin (n4), liver (n2) and multi-organ involvement (n4).
Eleven children were given daclizumab; one was treated with
inﬂiximab and 4 with their combination. Fourteen children re-
ceived a full course of monoclonal antibodies for aGVHD. An
additional child died after the ﬁrst dose and one child developed
reactive arthritis attributed to daclizumab. Eight of the 14 children
who completed treatment (57%) responded: ﬁve had CR and three
had a PR. Three children developed fatal fungal infection and one
had fatal adenovirus infection during or shortly after monoclonal
antibody treatment. Eight children died: Seven from Transplant
Related Mortality (TRM) and 1 due to relapse. Median length of
follow up in the remaining 8 patients was 20 months.
Conclusion: Monoclonal antibodies were effective in the treat-
ment of children with corticosteroid-resistant acute GVHD. The
risk for infection, mainly fungal, was high.
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MUTANT INOSINE MONOPHOSPHATE DEHYDROGENASE II PROVIDES
SELECTIVE ADVANTAGE TO TRANSDUCED CELL LINES ABOVE WILD
TYPE
Schroeder, M.A.1, Rettig, M.P.1, Ritchey, J.K.1, DiPersio, J.F.1 1Wash-
ington University School of Medicine, Division of Oncology, Saint Louis,
MO.
Nonmyeloablative conditioning regimens followed by allogeneic
hematopoietic cell transplantation relies on pre and post transplan-
tation immunosuppression to overcome host-versus-graft reactions
and control graft-versus-host-disease (GVHD). Lower donor chi-
merism predicts for higher rejection and relapse (Blood 2004;
104(8):2254). Immunosuppression may inhibit the beneﬁcial graft-
versus-infection and graft-versus-leukemia effects. Genetically
modifying T cells with a drug resistance gene is one way to confer
protection from the effects of immunosuppressive agents, retain
donor T cell function, and increase donor T cell chimerism.
Mycophenolate mofetil (MMF) has been used in the post trans-
plant setting to decrease GVHD and reduce host vs. graft reac-
tions. MMF’s active metabolite is mycophenolic acid (MPA),
which inhibits the enzyme inosine monophosphate dehydrogenase
(IMPDH). Its type II isoform is the rate-limiting enzyme in de
novo guanosine synthesis and is preferentially expressed in acti-
vated T and B cells. A number of investigators have identiﬁed
IMPDH II mutants that have altered MPA binding capacity and
normal guanosine synthetic activity ex vivo. We have generated six
mutants of IMPDH II and retrovirally transduced them into 3 cell
lines: human T cells (Jurkat), canine large granular lymphocytes
(CLGL-90) and ﬁbroblasts (NIH3T3). The mutants include:
S276A, S276F, T333I  S351Y (IY), L30F  Q277R, Q277R 
A462T, and S276Y. We generated bicistronic (IRES containing)
retroviral vectors that expressed either HA-tagged wild type hu-
man IMPDH II (WT) or an HA-tagged IMPDH mutant and
EGFP. Forced expression of WT will increase the MPA IC50 3
fold (IC50  3uM) compared to non-transduced cells. Forced
expression of only the IY mutant in all cell lines tested was able to
transfer resistance to MPA in excess of WT (IC5050uM). To
show that resistance was related to the expression of the mutant
enzyme we correlated GFP by FACS with HA-IMPDH II expres-
sion by western blot analysis, and correlated this with resistance to
MPA in vitro. This is the ﬁrst report where forced expression only
of the IY mutant provides a clear enhanced resistance to MPA in
vitro compared to cells over expressing wild type IMPDH II.
Currently, we are generating bicistronic maloney based oncoret-
roviral vectors which carry a suicide gene (CD34-TK) and the IY
mutant which will allow us to pharmacologically modulate the level
of donor T cells after allogeneic stem cell transplantation.
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DONOR C3435T POLYMORPHISM IN THE MULTIDRUG RESISTANCE 1
(MDR1) GENE IS ASSOCIATED WITH THE INCIDENCE OF ACUTE AND
CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC
HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ALLOSCT)
Shimoni, A.1, Ostrovsky, O.1, Galski, H.1, Hardan, I.1, Shem-Tov, N.1,
Yerushalmi, R.1, Nagler, A.1 1Chaim Sheba Medical Center, Tel-
Hashomer, Israel.
GVHD is the most signiﬁcant complication of alloSCT. HLA,
KIR and cytokine gene polymorphisms are involved in determin-
ing the risk of GVHD. The current study was designed to explore
the role of MDR1 gene polymorphism in predicting GVHD.
Single nucleotide polymorphisms at C3435T and G2677T were
determined in patients (pts) and donors using RFLP- based assay
and correlated with the occurrence GVHD. The study included
115 pts with various hematological malignancies after alloSCT
from related (n73) or unrelated (n42) donors. Fifty pts had
myeloablative and 65 had reduced-intensity conditioning. C3435T
polymorphism included CC, CT and TT genotypes that were
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